A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with ...

Little information has emerged about osavampator, a potentially first-in-class drug, since its promising Phase II performance last spring.

(HealthDay News) — Heavy alcohol use is associated with depression among U.S. retirees, according to a study published online Jan. 10 in Aging & Mental Health.

If seasonal depression is affecting your ability to function at home or work or in relationships, it may be time to reach out to your doctor.

NeuroStar is committed to advancing the body of scientific research and elevating mental health treatment through robust research and data-driven innovation,” stated Keith J. Sullivan, President and ...

The following is a summary of “Risks of adverse events with mirtazapine for adults with major depressive disorder: a ...

(HealthDay News) — Preventive psychological interventions may be effective for adults with subthreshold depressive symptoms, according to a review published online in the December issue of The Lancet ...

People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

The scientific literature has highlighted the role of inflammation in major depressive disorder (MDD), permeating several states of the disease. In chronic ...

Neurocrine Biosciences amended its agreement with Takeda Pharmaceutical regarding the development and commercialization of osavampator, a treatment for major depressive disorder.

CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

(HealthDay News) — The US Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at ...